CCTST "T1 Awardees Announced
The CCTSTs Pilot & Collaborative Studies (PCS) core has announced $1.3 million in FY2013 awards to facilitate T1 research.
T1 (Translation 1) research seeks to apply clinical or basic research knowledge in an identifiable pathway toward the development of trials and studies in humans.
Included were 11 full T1 awards of up to $100,000, four junior T1 awards of up to $25,000 and two innovative core service awards of up to $50,000. Four of the T1 awards and two of the Junior T1 awards included UC-CCHMC cross-institutional/interdisciplinary collaborations.
This was the fourth annual funding round of T1 grants, which expanded the highly successful Translational Research Initiative (TRI) at CCHMC to investigators across the AHC and UC west campus.
- Raouf Amin, MD, pulmonary medicine, CCHMC
- Hermine Brunner, MD, MSc, rheumatology, CCHMC
- Pankaj Desai, PhD, pharmacy, UC
- Sonata Jodele, MD, bone marrow transplantation & immune deficiency, CCHMC
- Michael Jordan, MD, immunobiology, CCHMC
- Robert McNamara, PhD, psychiatry, UC
- Marshall Montrose, PhD, molecular & cellular physiology, UC
- James Mulloy, PhD, experimental hematology & cancer biology, CCHMC
- Charles Quinn, MD, MS, hematology, CCHMC
- Kimberly Risma, MD, PhD, allergy & immunology, CCHMC (2nd year)
- Takuji Suzuki, PhD, pulmonary biology, CCHMC
- Aimee Dietz, PhD, allied health sciences, UC
- Yu Li, PhD, radiology, CCHMC
- Karen Ryan, PhD, endocrinology, diabetes & metabolism, UC
- Yuhang Zhang, pharmacy and dermatology, UC
- Prasad Devarajan, MD, nephrology, CCHMC
- Charles Dumoulin, PhD, radiology, CCHMC
Tags
Related Stories
UC physician-researcher's work yields landmark five-year data for Crohn's disease drug
June 8, 2026
The University of Cincinnati College of Medicine’s Anita Afzali, MD, leads a landmark study revealing five-year efficacy and safety data for a Crohn’s disease drug called guselkumab.
Certain weather patterns can trigger migraines
June 8, 2026
Certain weather patterns really do trigger migraine headaches — and the incidence is more common in the Midwest. As WGN 9 in Chicago recently reported, researchers at the University of Cincinnati College of Medicine have identified two specific weather patterns associated with an increased risk of headaches.
UC expert weighs in on current MASH treatment approaches
June 5, 2026
As MedCentral recently reported, pending broader pharmacologic approvals for metabolic dysfunction-associated steatohepatitis (MASH), lifestyle modifications remain the go-to intervention.